Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- Raltegravir was the first INSTI to be approved for the treatment of HIV infection and has been studied extensively as part of regimens for treatment-experienced patients[Steigbigel 2008]
- It has been studied as a switch regimen primarily to improve tolerability but is currently less favored than other INSTIs because it is administered twice daily and has a lower barrier to resistance than dolutegravir or bictegravir/emtricitabine/tenofovir AF
- Studies evaluating switches in suppressed patients receiving stable lopinavir/ritonavir-based antiretroviral therapy switched to raltegravir found improvements in serum lipids
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Switch Strategies